Physician profile
Michael D Sweeten
NPI 1952520058
$1,163.98
in general payments reported to CMS, 2019-2025
11 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.05 · 2022: $147 · 2023: $203 · 2024: $287 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $369.64 | 2022-2025 | Proclaim |
| Boston Scientific Corporation | $182.60 | 2023-2024 | Intracept |
| Stryker Corporation | $159.11 | 2025 | Spinejack, Mild Device Kit |
| Nevro Corp. | $155.15 | 2021-2024 | Senza |
| Spr Therapeutics, INC | $130.00 | 2025 | Sprint Pns System |
| Radius Health, INC. | $47.23 | 2021 | |
| Fidia Pharma USA INC. | $39.44 | 2025 | Triluron |
| Medtronic, INC. | $36.35 | 2022-2023 | Kyphon Express II Kyphopak Tray |
| Ferring Pharmaceuticals INC. | $16.05 | 2023 | Euflexxa |
| Nalu Medical, INC. | $14.43 | 2025 | Nalu Neurostimulation System |
| Bioventus LLC | $13.98 | 2023 | Gelsyn-3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sweeten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.